S&CO Inc. Raises Holdings in Edwards Lifesciences Corporation (NYSE:EW)

Key Points

• S&CO Inc. increased its holdings in Edwards Lifesciences Corporation by 34.2% during the first quarter, acquiring an additional 21,115 shares, bringing their total ownership to 82,797 shares worth approximately $6 million.
• Analyst ratings for Edwards Lifesciences are predominantly positive, with an average target price of $85.00 and reports indicating a mix of "buy," "hold," and "neutral" ratings.
• Insider trading activity has seen significant sales, with VP Donald E. Bobo, Jr. selling 2,570 shares and another insider, Larry L. Wood, selling 8,950 shares, indicating a decrease in their stock ownership.

S&CO Inc. boosted its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 34.2% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 82,797 shares of the medical research company's stock after buying an additional 21,115 shares during the quarter. S&CO Inc.'s holdings in Edwards Lifesciences were worth $6,001,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Prosperity Consulting Group LLC boosted its stake in Edwards Lifesciences by 3.6% during the fourth quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company's stock worth $289,000 after buying an additional 134 shares during the period. Arlington Trust Co LLC boosted its stake in Edwards Lifesciences by 1.2% during the first quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company's stock worth $804,000 after buying an additional 135 shares during the period. Valeo Financial Advisors LLC boosted its stake in Edwards Lifesciences by 2.8% during the first quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company's stock worth $372,000 after buying an additional 142 shares during the period. Versant Capital Management Inc boosted its stake in Edwards Lifesciences by 9.3% during the first quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company's stock worth $123,000 after buying an additional 145 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its stake in Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after buying an additional 145 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 2,570 shares of Edwards Lifesciences stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $77.40, for a total value of $198,918.00. Following the transaction, the vice president owned 50,356 shares in the company, valued at $3,897,554.40. The trade was a 4.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 34,962 shares of company stock valued at $2,641,387 over the last three months. Corporate insiders own 1.29% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on EW. JPMorgan Chase & Co. lifted their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a research note on Friday, July 25th. Morgan Stanley lifted their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock an "equal weight" rating in a research note on Tuesday, July 15th. Dbs Bank raised shares of Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Deutsche Bank Aktiengesellschaft lifted their target price on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday, July 25th. Finally, Canaccord Genuity Group lifted their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a research report on Friday, July 25th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, thirteen have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $85.71.

Edwards Lifesciences Stock Down 0.0%

Shares of EW stock traded down $0.01 on Friday, hitting $79.30. The stock had a trading volume of 3,150,719 shares, compared to its average volume of 4,584,635. The business has a 50 day moving average price of $76.82 and a 200 day moving average price of $73.74. Edwards Lifesciences Corporation has a one year low of $59.41 and a one year high of $83.00. The company has a quick ratio of 3.66, a current ratio of 4.45 and a debt-to-equity ratio of 0.06. The company has a market cap of $46.52 billion, a PE ratio of 11.41, a P/E/G ratio of 3.93 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.25% and a net margin of 72.96%. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the previous year, the firm earned $0.70 earnings per share. The firm's quarterly revenue was up 11.9% compared to the same quarter last year. Research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.